Home > Insider Trading > Filing (0001209191-22-011074)

Filing Details

Accession Number:: 0001209191-22-011074
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-02-17 21:00:20
Reporting Period:: 2022-02-15

Accepted Time:: 2022-02-17 21:00:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1655759	Arvinas Inc.	ARVN	Pharmaceutical Preparations (2834)	472566120

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753281	Ian Taylor	C/O Arvinas, Inc. 5 Science Park, 395 Winchester Ave. New Haven CT 06511	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-02-15	20,000	$19.36	98,645	No	4	M	Direct
Common Stock	Disposition	2022-02-15	5,867	$71.74	92,778	No	4	S	Direct
Common Stock	Disposition	2022-02-15	5,766	$72.55	87,012	No	4	S	Direct
Common Stock	Disposition	2022-02-15	4,126	$73.68	82,886	No	4	S	Direct
Common Stock	Disposition	2022-02-15	3,841	$74.64	79,045	No	4	S	Direct
Common Stock	Disposition	2022-02-15	300	$75.80	78,745	No	4	S	Direct
Common Stock	Disposition	2022-02-15	100	$76.58	78,645	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2022-02-15	20,000	$19.36	20,000	$19.36

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
37,633		2029-02-28	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.14 to $72.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.15 to $73.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.16 to $74.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.16 to $75.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.52 to $76.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
This option award was granted on March 1, 2019. 1/4 of the shares underlying the award vested on March 1, 2020, with the remainder of the shares vesting in equal monthly installments through March 1, 2023.